Financial Performance - The company's revenue increased by 37.5% to RMB 5,684 million[2,4] - Profit attributable to ordinary equity holders increased by 38.4% to RMB 590 million[2,4] - The core Xtep brand revenue reached RMB 4,898 million[2] - Interim dividend per share was HK 13.0 cents, with a payout ratio of 50.3%[2] Core Xtep Brand - Core Xtep brand revenue increased by 36.2% to RMB 4,898 million[10,55] - Xtep Kids' revenue increased by 84% to RMB 721 million, accounting for approximately 15% of the core Xtep brand's revenue[30] Athleisure (K-Swiss & Palladium) - Revenue increased by 36.3% to RMB 629 million[35] - Gross profit margin decreased by 3.7% points to 39.8%[35] Professional Sports (Saucony & Merrell) - Revenue increased by 106.4% to RMB 157 million[42,70] - Gross profit increased by 109.0% to RMB 90 million[42] Retail Network - There are 6,251 Xtep branded stores in Mainland China and overseas[2,27]

Financial Performance - Group revenue reached RMB 12,930 million, a 29.1% increase year-over-year[2,6] - Core Xtep brand revenue grew to RMB 11,128 million, representing a 25.9% increase[2,6] - Group's operating profit increased to RMB 1,464 million, a 4.9% increase[2,6] - Profit attributable to ordinary equity holders of the Company increased to RMB 922 million, a 1.5% increase[2,6] Core Xtep Brand Analysis - Core Xtep brand's operating profit increased to RMB 1,759 million, a 9.4% increase[2,81] - Core Xtep brand's net profit increased to RMB 1,345 million, a 10.7% increase[2,81] - Xtep Kids' revenue increased by 52% to RMB 1,671 million, accounting for 15% of the core Xtep brand's revenue in 2022[42] Brand Portfolio Performance - Athleisure brands (K-Swiss & Palladium) revenue increased by 44.4% to RMB 1,402 million[48,70] - Professional sports brands (Saucony & Merrell) revenue increased by 99.0% to RMB 400 million[55,70]

Xtep International Holdings Limited (Incorporated in the Cayman Islands with Limited Liability) Stock Code: 1368.HK 2023 Interim Results Presentation 23 August 2023 2023 Interim Results Highlights Core Xtep branded stores in Mainland China and overseas as at 30 June 2023 8,031 RMB 665 m 12.7% RMB 5,430 m 10.9% Core Xtep brand'srevenue Core Xtep brand's net profit RMB 871 m 12.7% RMB 6,522 m 14.8% Group's revenue Profit attributable to ordinary equity holders of the Company HK 13.7 cents Payout ratio: 50.0% ...

2023 Annual Results Presentation 18 March 2024 2023 Annual ResultsHighlights RMB 14,346 m 10.9% Group's revenue RMB 1,030 m 11.8% globally as at 31 December 2023 8,583 branded stores Core Xtep brand's revenue Profit attributable to ordinary equity holders of the Company Professional sports segment's revenue Athleisure segment's revenue (Mainland China) RMB 11,947 m RMB 796 m RMB 465 m HK 8.0 cents1 Full year payout ratio: 50.0% Final dividend per Share RMB 1,794 m 21.6% Group's inventories RMB 1,255 m 119.5 ...

Financial Performance - The group's revenue reached RMB 7,203 million, a 10.4% increase year-over-year[2] - Gross profit margin improved to 46.0%, up by 3.1 percentage points[3] - Profit attributable to ordinary equity holders of the company increased by 13.0% to RMB 752 million[4] - Interim dividend per share is HK15.6 cents, with a payout ratio of 50.0%[7] Brand Performance - Core Xtep brand revenue grew by 6.6% to RMB 5,789 million[9] - Professional sports segment revenue increased significantly by 72.2% to RMB 593 million[9] - Athleisure segment revenue increased by 9.7% to RMB 821 million[9] Balance Sheet Highlights - Net cash and cash equivalents increased by 51.7% to RMB 1,414 million[13] - Bank borrowings decreased by 22.6% to RMB 2,047 million[13] Sustainability - MSCI ESG rating upgraded to "A"[8] - Charity donations reached RMB 28.8 million[60]

Xtep International Holdings Limited (Incorporated in the Cayman Islands with Limited Liability) Stock Code: 1368.HK 2024 Annual Results Presentation 18 March 2025 2024 Annual Results Highlights Group's revenue RMB 13,577 m 6.5% RMB 1,250 m 57.2% Operating profit RMB 1,966 m 9.3% RMB 1,238 m Profit attributable to ordinary equity holders of the Company 20.2% Final dividend per Share 1 The proposed final dividend per Share will be subject to the approval of shareholders at the forthcoming annual general meeti ...

Group Financial Performance - Yue Yuen Group's revenue increased by 1.3% YoY to $2,029.5 million in 1Q25 [12, 48] - Profit attributable to owners decreased by 24.2% YoY to $75.8 million [37, 48] - Gross profit margin decreased by 2.2 percentage points to 22.9% [37, 48] Manufacturing Business - Manufacturing revenue increased by 5.9% YoY to $1,328.3 million in 1Q25 [37, 42, 61] - Shoe volume increased by 5.3% YoY to 61.9 million pairs [36, 44] - Average selling price (ASP) increased by 2.5% YoY to $20.04 per pair [36] - Manufacturing gross profit margin decreased by 2.6 percentage points to 17.7% [36, 37, 61] - Capital expenditure increased significantly by 239.2% YoY to $67.5 million [49, 83] Retail Business - Pou Sheng - Pou Sheng's revenue decreased by 5.4% YoY in RMB terms [37, 41] - Pou Sheng's online contribution reached a historical high, accounting for 32% of total sales, up 20% YoY [40, 93] - Profit attributable to owners of Pou Sheng decreased by 20.7% YoY [37, 94] - Same Store Sales Growth increased 13.9% YoY [93]

12 May 2025 Pou Sheng International 2025 1Q Results Disclaimer Yue Yuen and Pou Sheng have taken every reasonable care in preparing this presentation. However, please be reminded that the information, materials, opinions and statements contained or referred to in this presentation are all provided on an "as is" basis. None of the aforesaid information, materials, opinions and statements constitutes or will be viewed as investment advice or an offer, or a solicitation, recommendation or suggestion by Yue Yue ...

CANbridge Pharmaceuticals Corporate Presentation Aug 2023 Disclaimer THIS DOCUMENT OR THE INFORMATION CONTAINED HEREIN IS NOT INTENDED TO AND DOES NOT CONSTITUTE ANY OFFER OR INVITATION, SOLICITATION, COMMITMENT OR ADV ERTISEMENT OF ANY OFFER FOR SUBSCRIPTION, PURHCASE OR SALE OF ANY SECURITIES, NOR SHALL ANY PART OF THIS DOCUMENT FORM THE BASIS OF OR BE RELIED ON IN CONNECTION WITH ANY CONTRACT OR COMMITMENT WHATSOEVER. This document contains strictly conf idential and proprietary inf ormation in relation ...

Financial Performance - Revenue increased by RMB 225 million, a 184% year-over-year increase, primarily due to the commercialization of Nerlynx® in Taiwan in December 2020 and Hunterase® in mainland China in May 2021[134, 145] - R&D expenses decreased by RMB 1165 million, a 424% year-over-year decrease, mainly due to decreased payments to licensing partners[135, 145] - Cash balance increased by RMB 385 million, a 368% year-over-year increase, primarily attributed to the initial public offering in 2H 2021[133, 160] - Administrative expenses increased by RMB 27 million, a 50% year-over-year increase, primarily due to increased administrative employee costs and office expenses[145, 160] - The company's loss for the period was RMB 249 million in 1H 2022[146] Pipeline and Clinical Development - CANbridge identified 539 MPS II patients, and Hunterase has entered into 47 commercial insurance programs[37, 44, 135] - CAN108 NDA has been filed in mainland China and Taiwan for ALGS[41, 62] - The first patient was dosed in the Phase 1/2 trial for CAN103 in adult and adolescent patients with Gaucher disease in July 2022[47, 104] - CAN106 Phase 1 SAD study showed complete blockade of complement function, encouraging further studies in patients with PNH[70, 82] Strategic Initiatives - CANbridge opened a US-based Gene Therapy R&D center in Burlington, MA[47] - CANbridge formed a Complement Disease Scientific Advisory Board[47, 87]